A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...
Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP ...
Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and ...
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the ...
News-Medical.Net on MSN5d
Phase 1 trial examines safety and feasibility of stem cell treatment for Parkinson'sA recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...
CERo Therapeutics (CERO) announces the execution of an agreement with contract research organization CellCarta to manage translational assays ...
Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine.
The European Medicines Agency and Belgium’s Federal Agency for Medicines and Health Products have approved a Phase 2 challenge study on EV25, an antiviral therapeutic from Eradivir. The approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback